Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $3.10 billion. The enterprise value is $2.21 billion.
| Market Cap | 3.10B |
| Enterprise Value | 2.21B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 142.61 million shares outstanding. The number of shares has increased by 9.43% in one year.
| Shares Outstanding | 142.61M |
| Shares Change (YoY) | +9.43% |
| Shares Change (QoQ) | +8.06% |
| Owned by Insiders (%) | 13.72% |
| Owned by Institutions (%) | 84.60% |
| Float | 123.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.50 |
| Forward PS | 67.48 |
| PB Ratio | 2.13 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.79, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.79 |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -11.50% and return on invested capital (ROIC) is -12.86%.
| Return on Equity (ROE) | -11.50% |
| Return on Assets (ROA) | -10.40% |
| Return on Capital (ROIC) | -12.86% |
| Revenue Per Employee | $663,798 |
| Profits Per Employee | -$308,416 |
| Employee Count | 445 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.75% in the last 52 weeks. The beta is 1.36, so DNLI's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -26.75% |
| 50-Day Moving Average | 19.53 |
| 200-Day Moving Average | 19.44 |
| Relative Strength Index (RSI) | 53.54 |
| Average Volume (20 Days) | 1,528,075 |
Short Selling Information
The latest short interest is 8.86 million, so 6.21% of the outstanding shares have been sold short.
| Short Interest | 8.86M |
| Short Previous Month | 9.33M |
| Short % of Shares Out | 6.21% |
| Short % of Float | 7.19% |
| Short Ratio (days to cover) | 8.13 |
Income Statement
In the last 12 months, DNLI had revenue of $295.39 million and -$137.25 million in losses. Loss per share was -$0.97.
| Revenue | 295.39M |
| Gross Profit | 295.39M |
| Operating Income | -193.60M |
| Pretax Income | -137.22M |
| Net Income | -137.25M |
| EBITDA | -128.37M |
| EBIT | -137.22M |
| Loss Per Share | -$0.97 |
Balance Sheet
The company has $936.87 million in cash and $50.55 million in debt, giving a net cash position of $886.32 million or $6.22 per share.
| Cash & Cash Equivalents | 936.87M |
| Total Debt | 50.55M |
| Net Cash | 886.32M |
| Net Cash Per Share | $6.22 |
| Equity (Book Value) | 1.46B |
| Book Value Per Share | 10.21 |
| Working Capital | 890.99M |
Cash Flow
In the last 12 months, operating cash flow was -$412.81 million and capital expenditures -$12.30 million, giving a free cash flow of -$425.11 million.
| Operating Cash Flow | -412.81M |
| Capital Expenditures | -12.30M |
| Free Cash Flow | -425.11M |
| FCF Per Share | -$2.85 |
Margins
Gross margin is 100.00%, with operating and profit margins of -65.54% and -46.46%.
| Gross Margin | 100.00% |
| Operating Margin | -65.54% |
| Pretax Margin | -46.45% |
| Profit Margin | -46.46% |
| EBITDA Margin | -43.46% |
| EBIT Margin | -46.45% |
| FCF Margin | -143.92% |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.43% |
| Shareholder Yield | -9.43% |
| Earnings Yield | -4.43% |
| FCF Yield | -13.71% |
Analyst Forecast
The average price target for DNLI is $40.22, which is 85.01% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.22 |
| Price Target Difference | 85.01% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 16.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNLI has an Altman Z-Score of 14.31 and a Piotroski F-Score of 3.
| Altman Z-Score | 14.31 |
| Piotroski F-Score | 3 |